Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Understand the cost of Beyfortus (Nirsevimab) for RSV prevention in infants. Learn about insurance coverage, financial assistance programs, and essential questions to ask your doctor to protect your child from severe RSV.
Confused about whether CBD can get you high? Understand the difference between CBD and THC, their effects on your body, and what to look for in safe, non-intoxicating CBD products.
April 1, 2026
Learn about anticoagulants and antiplatelet drugs, often called blood thinners. Understand how they prevent blood clots, when they're prescribed, their side effects, and essential safety tips for Indian readers.
April 1, 2026
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, for infants, especially those under 6 months old, and young children with certain health conditions, RSV can lead to severe lung infections like bronchiolitis and pneumonia, requiring hospitalization. Each year, RSV is a leading cause of infant hospitalization in the United States. Fortunately, medical science has advanced, offering new tools for prevention. Beyfortus (nirsevimab) is a groundbreaking monoclonal antibody designed to protect infants and young children from severe RSV disease.
As a relatively new preventative option, many parents and caregivers are understandably concerned about the cost of Beyfortus and how to access this vital protection for their children. This comprehensive guide aims to demystify the cost of Beyfortus, explore insurance coverage options, highlight financial assistance programs, and provide essential information about RSV itself, empowering you to make informed decisions for your child's health.
RSV symptoms often mimic those of a common cold, typically appearing in stages rather than all at once. In older children and adults, symptoms are usually mild and may include:
However, in infants and young children, especially those under 6 months, RSV can cause more severe symptoms:
RSV is caused by a virus that spreads through respiratory droplets when an infected person coughs or sneezes. It can also spread through direct contact with contaminated surfaces (e.g., toys, doorknobs) and then touching the face, eyes, or nose. The virus can survive on surfaces for several hours and on hands for about 30 minutes. RSV is highly contagious, and outbreaks typically occur during fall, winter, and spring.
Diagnosing RSV usually begins with a physical examination and a review of symptoms. Your doctor may listen to your child's lungs for wheezing or other abnormal sounds. To confirm an RSV infection, a healthcare provider may perform a rapid diagnostic test using a nasal swab or aspirate, which can detect the virus in respiratory secretions.
It's crucial to understand that there is no specific antiviral medication to treat RSV infection directly. Treatment for RSV is primarily supportive, focusing on relieving symptoms and ensuring comfort. This may include:
Beyfortus is a preventative measure, not a treatment for active RSV infection.
While most RSV cases are mild, it's vital to know when to seek medical attention, especially for infants and high-risk children. Contact your pediatrician immediately or seek emergency care if your child exhibits any of the following:
Beyfortus (nirsevimab) is a long-acting monoclonal antibody developed to protect infants and young children against RSV disease. Unlike a traditional vaccine, which stimulates the body's immune system to produce its own antibodies, Beyfortus directly provides pre-formed antibodies to the infant. These antibodies help neutralize the RSV virus, offering immediate protection.
Beyfortus contains a single dose of nirsevimab, an antibody engineered to target a specific protein on the surface of the RSV virus. By binding to this protein, Beyfortus prevents the virus from entering cells and replicating, thereby protecting the infant from developing severe RSV disease. A single dose provides protection for at least five months, covering the typical RSV season.
The Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) recommend Beyfortus for:
It is administered as a single intramuscular injection, typically before or early in the RSV season.
The cost of Beyfortus is a significant consideration for many families. As a cutting-edge biological product, its price reflects the extensive research, development, and manufacturing processes involved.
The list price for a single dose of Beyfortus can vary, but generally, it is in the range of $495 to $600 per dose, depending on the dosage (50 mg for infants under 5 kg, 100 mg for infants 5 kg and over). This is the price set by the manufacturer before any discounts, insurance negotiations, or patient assistance programs are applied.
Several factors can influence the final cost you pay:
Before Beyfortus, Synagis (palivizumab) was the primary monoclonal antibody used for RSV prevention. However, Synagis requires monthly injections throughout the RSV season (typically 5 doses), and its use was generally restricted to very high-risk infants due to its high cost and the burden of multiple injections. Beyfortus, with its single-dose administration and broader recommendation, offers a more convenient and potentially more accessible option for a wider infant population. While a single dose of Beyfortus may have a higher per-dose list price than Synagis, the overall cost and convenience advantage can be significant.
Insurance coverage is a critical aspect of making Beyfortus accessible. Due to its recommendation by the CDC's Advisory Committee on Immunization Practices (ACIP), Beyfortus is generally covered by most insurance plans.
Most commercial health insurance plans are expected to cover Beyfortus, especially given its ACIP recommendation. However, coverage details can vary:
It is highly recommended to contact your insurance provider directly to understand your specific plan's coverage for Beyfortus. Ask about: the drug's coverage, any associated co-pays or co-insurance, whether a deductible applies, and if prior authorization is needed.
Under the Affordable Care Act (ACA), most recommended immunizations and preventive services are covered without cost-sharing. As an ACIP-recommended preventative, Beyfortus is expected to be covered by Medicaid and the Children's Health Insurance Program (CHIP) for eligible infants and children, usually with no out-of-pocket costs for families.
TRICARE, the healthcare program for uniformed service members, retirees, and their families, also typically covers ACIP-recommended vaccines and preventative medications. Other government-funded programs may also provide coverage. Check with your specific program administrator for details.
The Vaccines for Children (VFC) program is a federal program that provides vaccines at no cost to children who might not otherwise be vaccinated because of inability to pay. This includes children who are Medicaid-eligible, uninsured, underinsured, or American Indian/Alaska Native. Given Beyfortus's role in prevention, it is included in the VFC program, making it accessible to a significant portion of the eligible population.
Even with insurance, out-of-pocket costs can be a barrier for some families. Fortunately, several financial assistance programs may help reduce the burden.
The manufacturer of Beyfortus (Sanofi and AstraZeneca) may offer patient assistance programs to help eligible individuals with the cost of the medication. These programs often assist with co-pays, deductibles, or even provide the medication at no cost to uninsured or underinsured patients who meet specific income criteria. Check the official Beyfortus website or contact the manufacturer's patient support line for information on available programs.
Various non-profit organizations and foundations dedicated to child health or respiratory diseases may offer financial assistance or resources to families struggling with medication costs. Searching for patient advocacy groups related to RSV or pediatric health can be a good starting point.
Some hospitals and clinics offer their own financial assistance programs or charity care policies for patients who cannot afford necessary medical services. Inquire with the billing or patient financial services department at the facility where your child will receive Beyfortus.
Open communication with your pediatrician or healthcare provider is key to understanding both the medical necessity and the financial implications of Beyfortus. Here are some questions to ask:
Confused about Plan B and abortion pills? Understand the key differences, how they work, and their effectiveness for informed reproductive health decisions.
April 1, 2026